Grants Search Results

Through this partnership with The Children's Cancer Foundation, proceeds from St. Baldrick's events in Hong Kong fund life-saving research in Hong Kong. The St. Baldrick's Foundation is proud to partner with the Children's Cancer Foundation and has been doing so since 2008.

Through this partnership with The Children's Cancer Foundation, proceeds from St. Baldrick's events in Hong Kong fund life-saving research in Hong Kong.

Proceeds raised through St. Baldrick's head-shaving events in Belgium now proudly support the Olivia Hendrickx Research Fund, an organization with the mission is to improve the chances of survival for children with cancer. They do this by supporting innovative research in a constructive way.

Through this partnership with The Children's Cancer Foundation, proceeds from St. Baldrick's events in Hong Kong fund life-saving research in Hong Kong. The St. Baldrick's Foundation is proud to partner with the Children's Cancer Foundation and has been doing so since 2008.

This grant funded one project. Relapsed or refractory neuroblastoma is the most common extracranial solid tumor found in Hong Kong pediatric cancer patients; however there is no standard therapy yet, and the 5-year overall survival after disease relapse was only about 20%. This clinical study aims to evaluate the efficacy and safety of the treatment of quadruple immunotherapy with the NK cells, anti-GD2 antibody, cytokines and RXRg agonist spironolactone, and also the NK cell chimerism and persistence after adoptive NK cell transfer, in order to examine if this treatment could become a therapeutic option for cases in Hong Kong.

Through this partnership with The Children's Cancer Foundation, proceeds from St. Baldrick's events in Hong Kong fund life-saving research in Hong Kong. The St. Baldrick's Foundation is proud to partner with the Children's Cancer Foundation and has been doing so since 2008.

This grant funded two projects. Project 1: Acute lymphoblastic leukemia (ALL) is a common childhood cancer. The survival rate for children with good risk factors is over 90% with low-intensity chemotherapy. However, children with high-risk disease have a higher chance of treatment failure and relapse. Two genetic mutations, MEF2D and KMT2A, have been found to have poor outcomes with conventional chemotherapy. The Chinese Children Cancer Group (CCCG) ALL 2020 protocol in Hong Kong Children's Hospital is adding the drug bortezomib to the treatment to improve outcomes for high-risk patients with these mutations. Project 2: patients with chemotherapy. However, 2-4% of patients under one year old, known as infant ALL, have a low survival rate of about 40%, especially when there is a genetic change involved. This patient group experiences more relapses in the bone marrow and central nervous system. Previous clinical trials have shown limited success. This project aims to improve the treatment of infant ALL with three new drugs: blinatumomab, venetoclax, and bortezomib. The study involves more than 20 hospitals in Hong Kong and mainland China, and patients will be monitored closely for safety and effectiveness.

Through this partnership with The Children's Cancer Foundation, proceeds from St. Baldrick's events in Hong Kong fund life-saving research in Hong Kong. The St. Baldrick's Foundation is proud to partner with the Children's Cancer Foundation and has been doing so since 2008.

This grant funded two projects. Project 1: Chemotherapeutic agents for the treatment of a wide variety of cancer types are associated with potentially lethal cardiac damage. The study develops diagnostic biomarkers and therapeutic targets for chemotherapeutic-induced cardiotoxicity, which can aid in the diagnosis of it and reveal new therapeutic targets for the treatment of this kind of disorder. Project 2: Children suffering from relapsed / refractory acute myeloid leukemia have an extremely poor prognosis with limited treatment options. The development of novel therapeutics is, therefore, among the top priorities of scientific and medical communities.

Through this partnership with The Children's Cancer Foundation, proceeds from St. Baldrick's events in Hong Kong fund life-saving research in Hong Kong. The St. Baldrick's Foundation is proud to partner with the Children's Cancer Foundation and has been doing so since 2008.

This grant funded three projects. Project 1: A five-year study on Paediatric Hepatic International Tumour Trial (PHITT) in Hong Kong. Project 2: An extension of a parallel study with the Chinese children cancer group relapsed acute lymphoblastic leukemia 2017 Study (CCCG relapsed ALL 2017). Project 3: A New Clinical trial protocol for children with acute promyelocytic leukemia (APL) in Hong Kong.

Through this partnership with The Children's Cancer Foundation, proceeds from St. Baldrick's events in Hong Kong fund life-saving research in Hong Kong. The St. Baldrick's Foundation is proud to partner with the Children's Cancer Foundation and has been doing so since 2008.

This grant funded two projects. Project 1: The early bone marrow relapse in Acute lymphoblastic Leukemia has a low remission rate. Previous case studies showed that adding a new agent, Bortezomib, on top of the Rituximab, together with intensive chemotherapy, may achieve remission for adults. The study aims to add this new agent Bortezomib to paediatric treatment to improve survival rate. Project 2: Previous studies showed that MRD monitoring of Acute Lymphoblastic Leukemia is a very important tool to guide the stratification of treatment. This study introduces a new penal of antibodies to improve accuracy and sensitivity for MRD monitoring and aims at developing a more cost-effective approach of MRD monitoring in Hong Kong.

Through this partnership with The Kids' Cancer Project, proceeds from St. Baldrick's events in Australia fund life-saving research in Australia.

Through this partnership with the Children's Cancer Foundation, proceeds from St. Baldrick's head-shaving events in Hong Kong support life-saving childhood cancer research in Hong Kong. The St. Baldrick's Foundation is proud to partner with the Children's Cancer Foundation and has been doing so since 2008. This grant has funded two projects. The first project is an extension of a previous grant. Researchers collect the tissues of all pediatric brain tumors in Hong Kong to review and perform special tests. The results will refine diagnoses and categorization, offers much better prognosis and more precise therapy. The second project is also an extension of a previous grant, building on the work showing that rituximab combined with chemotherapy improves survival rate in patients with acute lymphoblastic leukemia. This year's extension will study how adding bortezomib to rituximab and chemotherapy improves remission rates.

Through this partnership with the Children's Cancer Foundation, proceeds from St. Baldrick's head-shaving events in Hong Kong support life-saving childhood cancer research in Hong Kong. This grant has funded two projects. The first project is an extension of a previous grant. It aims to accurately measure treatment response by identifying and counting residual leukemia cells in patients following treatment to avoid under-or over-treatment of the disease in the future. The ultimate goal of this project is to develop a more cost-effective approach of MRD monitoring that helps avoid under- or over-treatment of childhood leukemia, while achieving a higher cure rate and long-term event-free survival. The second project is a pre-clinical investigation on the role of CD9 as an inhibitor of pediatric acute myeloid leukemia by regulating leukemia progression and chemosensitivity. If proven, the new CD9-targeting agents could be developed as an add-on to conventional chemotherapy for treatment of high-risk and relapsed pediatric AML.

Through this partnership with the Children's Cancer Foundation, proceeds from St. Baldrick's head-shaving events in Hong Kong support life-saving childhood cancer research in Hong Kong. This grant has funded four projects. The first project is an extension of a previous grant. It aims to accurately measure treatment response by identifying and counting residual leukemia cells in patients following treatment to avoid under-or over-treatment of the disease in the future. The second project explores cardiac diseases and diseases of the circulatory system, these remain to be important causes of cumulative mortality in the long-term for child cancer patients after cancer therapy. These studies based on multi-modality evaluation of cardiac function, will give long-term monitoring and assessment of treatment-related cardiotoxicity in pediatric cancer survivors. The third project is a study to improve the cure rate of childhood acute lymphoblastic leukemia. The research also includes studying any impact of special genetic changes on the treatment outcome. The fourth project aims at investigating the prevalence of sexual and reproductive problems caused by childhood cancer treatment amongst local childhood cancer survivors by conducting questionnaires to assess various aspects, including sexual function, self-esteem and general well-being of a group of patients.

Through this partnership with the Children's Cancer Foundation, proceeds from St. Baldrick's head-shaving events in Hong Kong support life-saving childhood cancer research in Hong Kong. This grant has funded four projects. The first project is an extension of a previous grant. It aims to accurately measure treatment response by identifying and counting residual leukemia cells in patients following treatment, as a result to avoid under-or over-treatment in the future. The second project explored palliative care needs. Palliative care plays an important role in improving symptom control and psychosocial care for pediatric cancer patients and their families. However, there are no international guidelines specifically made for pediatric palliative care (PPC), with the exception of pain management. A local study is thus needed to explore how PPC can be improved and to identify the essential skills, facilities and services needed in the provision of such care in Hong Kong hospitals and community settings. The third project is a study of a large inter-group randomized trial on whether rituximab (antibody) can add benefit to the current chemotherapy regimen for children and adolescents with high risk B cell non-Hodgkin lymphoma. The fourth project explored cardiac toxicity. Cardiac toxicity is one of the most concerning side effects of anti-cancer therapy. The gain in life expectancy obtained with anti-cancer therapy can be compromised by increased morbidity and mortality associated with its cardiac complications. The field of ‘pediatric cardo-oncology’ has emerged as an essential discipline to provide cardiac specialist care to pediatric cancer patients. In this project multi-modality evaluation on cardiac function is used to monitor the cardiac function of children after cancer therapy.

Through this partnership with German Childhood Cancer Foundation, proceeds from St. Baldrick's events in Germany fund life-saving research in Germany. St. Baldrick's is proud to partner with German Childhood Cancer Foundation and has been doing so since 2015.

Proceeds raised through St. Baldrick's head-shaving events in Singapore now proudly support the Duke-NUS Graduate Medical School Singapore (Duke- NUS) Pediatric Cancer Research Fund, a project which aims to uncover underlying causes of osteosarcoma (bone cancer), with the hope that this will lead to improved treatments.

Through this partnership with Bermuda Cancer and Health Centre proceeds from St. Baldrick's events in Bermuda fund the SunSmart program and life-saving research through the St. Baldrick's Foundation.

Through this partnership with the Children's Cancer Foundation, proceeds from St. Baldrick's head-shaving events in Hong Kong support life-saving childhood cancer research in Hong Kong. One of the two projects funded by this grant is an extension of pervious grant and aims to accurately measure treatment response by counting residual leukemia cells in patients following treatment. The second project is an European clinical trial studying the effectiveness of using antibody treatment together with chemotherapy and surgery for patients with newly diagnosed neuroblastoma.

Through this partnership with CHILDREN with CANCER UK proceeds from St. Baldrick's events in the United Kingdom fund life-saving childhood cancer research in the United Kingdom. St. Baldrick's is proud to partner with CHILDREN with CANCER UK and has been doing so since 2013.

Through this partnership with Children's Leukaemia Research Project proceeds from St. Baldrick's events in Ireland fund life-saving childhood cancer research in Ireland.

Through this partnership with the Children's Cancer Foundation, proceeds from St. Baldrick's head-shaving events in Hong Kong support life-saving childhood cancer research in Hong Kong. One of the two projects funded by this grant establishes a centralized molecular genetic and chromosome analysis testing service for the diagnosis of pediatric solid tumor cancers. The second is an extension of previous grant and aims to accurately measure treatment response by counting residual leukemia cells in patients following treatment.